The pharmaceutical giant Sanofi announced Tuesday, February 2 its intention to remove “approximately 600 positions over the next three years” in France, 2% of the workforce, through voluntary departures and early retirement financing. This “evolution of (the) organization” project “no provision for plant closure and will have no impact on the number of R & amp; D” (research and development), ensures the group in a statement. Departures will be “on a voluntary basis,” insisted a spokesman.
According to information gathered by AFP from the CGT, following various meetings of bodies Staff Tuesday, total year 1098 positions must be eliminated, including 657 currently occupied (the others being vacant, particularly in R & amp; D where 296 unfilled positions will be eliminated). According to the CGT and CFDT, the most affected subsidiary is pharmaceutical production SWI (-400 positions held), followed by commercial subsidiary SAF (-155), SAG headquarters central services (-102).
The reorganization must be done in two years “by the end of 2017″ according to the CGT and CFDT. It also includes the “legal transfer” of 870 stations to the central services, said the CFDT, “nearly 1,000″ according to the CGT. This is particularly the case of 175 positions with Pasteur (vaccines), where the reorganization will not pass through a social plan.
The group, which employs 27,000 workers in France on about 110,000 people worldwide, announced in November a plan to save 1.5 billion euros by 2018 through a refocusing of its portfolio of activities and reorganization of the company into five business units. Sanofi was then quantified the impact for France “several hundred jobs per year over a period of three years”.
(With AFP)
No comments:
Post a Comment